At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 66 enrolled
Drug / intervention
Testosterone enanthate auto-injectorcombination
Likely dose
Testosterone enanthate auto-injector 50 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label Study to Evaluate the Safety of Testosterone Enanthate After Two Single-Dose Injections Via QuickShot® Testosterone by Intended Users and QuickShot™ Summative Usability Study
In Brief
A Phase 2 clinical trial evaluating Testosterone enanthate auto-injector for Hypogonadism. Completed, enrolled 66 participants across 3 sites.
Detailed Summary
Evaluation of the safety and tolerability of testosterone enanthate (TE) following a single dose via QuickShot® Testosterone (QST) when administered by intended users in a usability study.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypogonadism
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedMay 2016
Enrollment StartJun 2016
Primary CompletionAug 2016
TodayJul 2026
First PostedMay 19, 2016
Enrollment StartJun 1, 2016
Primary CompletionAug 1, 2016
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 10.1 years ago
Interventions
Testosterone enanthate auto-injectorcombination
SC injections of QST 50 mg or 75 mg or 100 mg